Core Viewpoint - The article discusses the poor performance of actively managed equity funds established in 2021, with over 50% of them still showing negative returns despite the A-share market recovering above 4000 points [1]. Fund Performance Summary - A total of 667 actively managed equity funds established in 2021 were analyzed, revealing that approximately 362 funds have negative returns since inception, accounting for over 50% of the sample [1]. - Among these, 86 funds have experienced declines of over 30%, and 34 funds have seen declines exceeding 40% [1]. - Specific funds such as Qianhai Kaiyuan Public Health Theme Select and others have reported losses greater than 50% since their inception [1]. Specific Fund Data - Qianhai Kaiyuan Public Health Stock A/C, established on March 25, 2021, has a return of -57.80% and -58.60% as of February 5, 2026, with a cumulative loss nearing 60% [2]. - The fund's top ten holdings include companies like Tigermed, WuXi AppTec, and BeiGene [1]. - Qianhai Kaiyuan Public Health Stock A/C has a scale of 0.83 billion yuan as of December 31, 2025 [2]. Additional Fund Performance - Qianhai Kaiyuan Quality Enterprises 6-Month Holding Mixed A/C, established on January 8, 2021, has cumulative returns of -40.78% and -43.14% [3]. - The fund's top holdings include major companies such as Tencent and Alibaba, but its performance has been subpar since 2026 [4].

Core Viewpoint - North Chip Life Technology Co., Ltd. (stock code: 688712) has been listed on the Sci-Tech Innovation Board, raising nearly 1 billion yuan through the issuance of 57 million shares at a price of 17.52 yuan per share [1] Group 1: Financial Performance - The opening price of North Chip Life was 50.31 yuan, representing a 187% increase from the issuance price, with a market capitalization of 20.871 billion yuan at midday [3] - The company expects annual revenue between 520 million and 560 million yuan, reflecting a growth of 64.24% to 76.88% year-on-year [7] - Revenue for the first nine months of 2025 reached 407 million yuan, a 71.36% increase from 240 million yuan in the same period last year [7] - The projected net profit for the company in 2025 is between 78 million and 88 million yuan, indicating a year-on-year growth of 278.91% to 301.85% [7] Group 2: Company Overview - North Chip Life was established in 2015, focusing on cardiac interventional diagnostics, primarily developing, producing, and selling interventional and implantable medical devices [5] - The company’s FFR measurement system consists of the TruePhysio pressure microcatheter and the VivoCardio FFR measurement device, which aids in precise diagnosis and treatment of coronary artery disease [5] - The company reported revenues of 92.45 million yuan, 184 million yuan, and 317 million yuan for the years 2022, 2023, and 2024, respectively, with net losses of 300 million yuan, 155 million yuan, and 53.74 million yuan for the same years [5] Group 3: Shareholder Structure - Major investors include Sequoia Capital, Tiger Med, Qiming Venture Partners, and others, with Sequoia being the largest institutional shareholder [8] - Prior to the IPO, the actual controller, Song Liang, held 16.1530% of the shares directly and controlled an additional 13.414% through employee stock ownership platforms, totaling 29.5670% [8] - Post-IPO, Song Liang's direct shareholding decreased to 14.5377%, while Sequoia Capital's shareholding was reduced to 9.1583% [12][13]

Market Overview - On February 4, the medical services sector rose by 1.18% compared to the previous trading day, with Haitai Biological leading the gains [1] - The Shanghai Composite Index closed at 4102.2, up 0.85%, while the Shenzhen Component Index closed at 14156.27, up 0.21% [1] Medical Services Sector Performance - Haitai Biological (300683) closed at 32.72, up 8.56%, with a trading volume of 144,400 shares and a transaction value of 464 million [1] - MediX (688202) closed at 63.84, up 3.70%, with a trading volume of 46,200 shares and a transaction value of 289 million [1] - Other notable performers include: - Purui Eye Hospital (301239) at 35.56, up 2.92% [1] - Tigermed (300347) at 64.94, up 2.75% [1] - Kanglong Chemical (300759) at 30.37, up 2.57% [1] Capital Flow Analysis - The medical services sector saw a net inflow of 427 million from institutional investors, while retail investors experienced a net outflow of 439 million [2][3] - Notable net inflows from institutional investors include: - Tigermed (300347) with 158 million [3] - Aier Eye Hospital (300015) with 118 million [3] - WuXi AppTec (603259) with 112 million [3] Individual Stock Capital Flow - Tigermed (300347) had a net institutional inflow of 158 million, accounting for 14.54% of its trading volume [3] - Aier Eye Hospital (300015) had a net institutional inflow of 118 million, representing 12.46% of its trading volume [3] - Other stocks with significant institutional inflows include: - WuXi AppTec (603259) with 112 million [3] - Kanglong Chemical (300759) with 58.6 million [3]

智通财经2月4日讯（编辑 胡家荣）港股三大指数表现不一。截至收盘，恒生指数涨0.05%，报26847.32点；科技指数跌1.84%，报5366.44点；国企指数跌 0.05%，报9048.38点。 今日市场 从市场表现来看，煤炭、房地产、航空、医药等个股逆势走强，而SaaS、光通讯、AI应用等科技成长方向则普遍承压，市场情绪受内外因素交织影响。 焦炭首轮提涨落地 飞尚无烟煤领涨 截至收盘，飞尚无烟煤(01738.HK)涨20%、兖煤澳大利亚(03668.HK)涨11.05%、兖矿能源(01171.HK)涨10.58%。 | 代码 | 名称 | 最新价 | 涨跌额 | 涨跌幅 ◆ | | --- | --- | --- | --- | --- | | 01738 | 飞尚无烟煤 | 0.126 | +0.021 | +20.00% | | 01303 | 汇力资源 | 0.270 | +0.040 | +17.39% | | 03668 | 兖煤澳大利亚 | 34.980 | +3.480 | +11.05% | | 01171 | 究矿能源 | 12.440 | +1.190 | +10.58% | | 00 ...

Core Viewpoint - The healthcare sector is experiencing a significant rebound, with the largest healthcare ETF (512170) showing strong performance and attracting substantial capital inflows, indicating renewed investor interest in the sector [1][3][4]. Group 1: ETF Performance - The healthcare ETF (512170) rose over 1.4% after recovering from previous lows, successfully surpassing the 5-day and 60-day moving averages [1]. - The ETF has seen a continuous premium in trading, reflecting active buying interest, with a net inflow of 2.688 billion yuan over the last 12 trading days [3]. Group 2: Earnings Forecasts - As of now, 18 constituent stocks of the healthcare ETF have disclosed their earnings forecasts for 2025, with 11 expected to report profits. Notably, 12 stocks are projected to achieve double-digit growth [4]. - Specific companies like Lepu Medical are forecasting a net profit increase of 224% to 3.86 billion yuan, while other leading CXO firms like Zhaoyan New Drug and Boteng Co. are also expected to see substantial profit growth [4][5]. Group 3: Market Trends - The recovery in the global investment landscape, ongoing domestic support for the innovative drug sector, and a revival in new drug development are contributing to a positive outlook for the CXO industry [4]. - By 2026, structural reforms and improved policy and financing environments are expected to drive the Chinese pharmaceutical industry towards high-quality development [4]. Group 4: ETF Characteristics - The healthcare ETF (512170) is the largest in the market, with a fund size of 27.5 billion yuan, covering over 50% in medical devices and nearly 25% in CXO [6]. - The ETF includes 12 stocks related to AI medical and brain-computer interface concepts, providing a diversified investment opportunity in the healthcare sector [6].

Group 1 - The A-share market saw a rise in innovative drug concept stocks, with notable increases in companies such as Haitai Biological (up over 8%), Guangshengtang (up 7%), and Kangchen Pharmaceutical (up over 5%) [1] - The National Medical Products Administration announced strong support for the innovative development of the biomanufacturing industry during the "14th Five-Year Plan" period, aiming to shift the pharmaceutical industry from "follow-up innovation" to "systematic innovation" [1] Group 2 - Haitai Biological reported a rise of 8.63%, with a total market value of 4.285 billion [2] - Guangshengtang increased by 7.01%, with a total market value of 18.4 billion [2] - Kangchen Pharmaceutical rose by 5.46%, with a total market value of 6.607 billion [2] - Xintai increased by 4.20%, with a total market value of 53.6 billion [2] - Shutaishen rose by 3.94%, with a total market value of 1.3 billion [2] - Beilu Pharmaceutical increased by 3.49%, with a total market value of 584.3 million [2] - Tigermed rose by 3.37%, with a total market value of 56.3 billion [2]

Group 1 - The innovative drug sector experienced a significant upward trend on February 4, with notable gains in several companies [2] - HaiTe Bio saw an increase of over 8%, while GuangShengTang rose by more than 6% [2] - Other companies such as KangChen Pharmaceutical, ShuTaiShen, XinLiTai, BeiLu Pharmaceutical, and Tigermed also showed positive movement in their stock prices [2]

Group 1 - The A-share market saw a rise in innovative drug concept stocks, with notable increases in companies such as Haitai Biological (up over 8%), Guangshengtang (up 7%), and Kangchen Pharmaceutical (up over 5%) [1] - The National Medical Products Administration announced strong support for the innovation and development of the biomanufacturing industry during the "14th Five-Year Plan" period, aiming to shift the pharmaceutical industry from "follow-up innovation" to "systematic innovation" [1] Group 2 - Haitai Biological reported a rise of 8.63% with a total market value of 42.85 billion and a year-to-date increase of 18.07% [2] - Guangshengtang increased by 7.01%, with a total market value of 18.4 billion and a year-to-date increase of 29.53% [2] - Kangchen Pharmaceutical rose by 5.46%, with a total market value of 6.607 billion and a year-to-date increase of 4.53% [2] - Xintai increased by 4.20%, with a total market value of 53.6 billion and a year-to-date decrease of 2.89% [2] - Shutaishen and Beilu Pharmaceutical both saw increases of over 3%, with market values of 13 billion and 5.843 billion respectively [2]

2月3日，泰格医药涨4.97%，成交额10.32亿元。两融数据显示，当日泰格医药获融资买入额5393.21万 元，融资偿还5727.85万元，融资净买入-334.64万元。截至2月3日，泰格医药融资融券余额合计6.31亿 元。 截至9月30日，泰格医药股东户数4.84万，较上期减少6.01%；人均流通股0股，较上期增加0.00%。2025 年1月-9月，泰格医药实现营业收入50.26亿元，同比减少0.82%；归母净利润10.20亿元，同比增长 25.45%。 分红方面，泰格医药A股上市后累计派现24.58亿元。近三年，累计派现11.54亿元。 机构持仓方面，截止2025年9月30日，泰格医药十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股4836.25万股，相比上期增加2509.69万股。中欧医疗健康混合A（003095）位居第四大流 通股东，持股2885.17万股，相比上期增加121.78万股。华宝中证医疗ETF（512170）位居第五大流通股 东，持股1456.80万股，相比上期减少266.25万股。易方达创业板ETF（159915）位居第八大流通股东， 持股1125.86万股，相比上期减少 ...

Core Viewpoint - The ChiNext Medical Index (970082) closed at 3876.07 points on February 3, with a gain of 2.37% and a trading volume of 13.236 billion yuan, indicating positive market sentiment in the medical sector [1]. Group 1: Index Performance - The ChiNext Medical Index saw 49 constituent stocks rise, with NuoSiGe leading the gains at 8.76% [1]. - The index's turnover rate was 1.71%, reflecting moderate trading activity [1]. Group 2: Top Constituents - The top ten constituents of the ChiNext Medical Index include: - YuanEr Eye Hospital (sz300015) with a weight of 9.18% and a latest price of 11.04 yuan, up 1.28% [1]. - MaiRui Medical (sz300760) with a weight of 8.95% and a latest price of 188.15 yuan, up 0.56% [1]. - TaiGe Medical (sz300347) with a weight of 8.52% and a latest price of 63.20 yuan, up 4.97% [1]. - KangLong HuaCheng (sz300759) with a weight of 7.18% and a latest price of 29.61 yuan, up 2.10% [1]. - LePu Medical (sz300003) with a weight of 4.96% and a latest price of 17.83 yuan, up 1.89% [1]. - New Industry (sz300832) with a weight of 4.73% and a latest price of 54.50 yuan, up 2.60% [1]. - AiMeiKe (sz300896) with a weight of 4.49% and a latest price of 147.57 yuan, up 4.56% [1]. - YingKe Medical (sz300677) with a weight of 4.14% and a latest price of 40.55 yuan, up 1.38% [1]. - FuRui Medical (sz300049) with a weight of 3.55% and a latest price of 67.33 yuan, up 1.45% [1]. - HuaDa Gene (sz300676) with a weight of 3.15% and a latest price of 50.30 yuan, up 2.57% [1]. Group 3: Capital Flow - The net inflow of main funds into the ChiNext Medical Index constituents totaled 145 million yuan, while retail investors experienced a net outflow of 106 million yuan [1]. - The detailed capital flow indicates that TaiGe Medical had a main fund net inflow of 10.514 million yuan, while retail investors had a net outflow of 18.28% [2].